Clinical profile of FTL3-ITD mutation in West Algerian population with acute myeloid leukemia

Document Type : Original article


1 Department of biology, Faculty of Science and Technology, University of Ain Temouchent-Belhadj Bouchaib-, Algeria

2 Service de Cytogénétique et de Biologie moléculaire de l’Etablissement Hospitalo-universitaire d’Oran (1er Novembre)

3 École Supérieure en Sciences Biologiques d'Oran (ESSBO), BP 1042, Saim Mohamed 31003, Oran, Algeria

4 Université des sciences et de la technologie d’Oran Mohamed Boudiaf

5 Service d’hématologie et de thérapie cellulaire de l’Etablissement Hospitalo-universitaire d’Oran (1er Novembre)

6 Département de pharmacie, Faculté de Médecine, Université Oran1


Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the abnormal and rapid growth of cells. The mutation of the Fms-like tyrosine kinase 3 ligand gene (FLT3-ITD) represents an important factor in the prognosis of AML. The objective of this study was to determine for the first time the prevalence of FLT3-ITD mutation in west Algerian AML patients. A total of 160 AML patients were genotyped for FLT3-ITD mutation by using polymerase chain reaction. FLT3-ITD mutation was detected in 13% of patients. Mutation rates show no significant difference in the distribution of sex and age. A positive association was found between this mutation and a higher leukocyte and blast cells counts. We also found that the M3 and M5 subtype were the commonest in the FLT3 mutated group. This preliminary study provides first-time prevalence estimates for FLT3-ITD mutation in acute myeloid leukemia patients from the West region of Algeria.